Cai, Yi
Guo, Hao
Wang, Wenda
Li, Hanzhong
Sun, Hao
Shi, Bing
Zhang, Yushi
Funding for this research was provided by:
National Natural Science Foundation of China (81670611)
National Key Research and Development Program of China (2016YFC0901500)
Novartis Pharmaceuticals Corporation (I10288)
Article History
Received: 13 December 2017
Accepted: 8 March 2018
First Online: 27 March 2018
Ethics approval and consent to participate
: All patients provided written informed consent before entering the clinical trial. The study was done in accordance with the Declaration of Helsinki and local regulations This study protocol was approved by the Human Ethics Committee of Peking Union Medical College Hospital, before the first patient was enrolled.
: Not applicable.
: Yi Cai received travel expenses from Novartis CO., LTD. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.